Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new class of compounds that target a novel kinase involved in metabolic diseases has been discovered in a collaboration between Pharmacopeia and Biovitrum.
Subscribe to our email newsletter
The companies now plan to progress the development of the compounds into the next phase, focused on compound optimization and advancement of the program towards development.
Under the terms of the collaboration, which is focused on multiple targets, Biovitrum will be responsible for advancing the compounds through pre-clinical and clinical development and onto the market.
Pharmacopeia is entitled to receive milestone payments if collaboration programs progress into lead optimization and through clinical development. Additionally, if therapeutic products are marketed based on compounds derived from the collaboration, Pharmacopeia will be entitled to receive royalties on sales.
“Our work with Biovitrum has produced excellent results in short order, and we are confident that our companies’ complementary strengths will continue to drive success as we shift into the next phase of this collaboration,” said Dr Les Browne, president and chief executive officer of Pharmacopeia.